Skip to main content

Table 2 Characteristics of patients with COPD

From: Suppressor of variegation 3–9 homologue 1 impairment and neutrophil-skewed systemic inflammation are associated with comorbidities in COPD

Variables

COPD patients (n = 213)

Male, n (%)

193 (90.6)

Age, years (mean ± SD)

73.1 ± 8.4

BMI (mean ± SD)

23.57 ± 4.11

Cigarette smoking, n (%)

 

Current smoker

80 (37.5)

Ex-smoker

113 (53.1)

Never smoker

20 (9.4)

Comorbidities, n (%)

 

Heart failure

17 (7.98)

Coronary artery disease

54 (25.35)

Pulmonary hypertension

28 (13.15)

Lung cancer

3 (1.4)

Anxiety/depression

9 (4.2)

Osteoporosis

12 (5.63)

Malnutrition (BMI < 20)

38 (17.84)

Diabetes mellitus

34 (15.96)

OSA

8 (3.76)

Normocytic anemia

26 (12.2)

Lung fibrosis

14 (6.57)

Charlson comorbidity index score; median (IQR)

5 (4–6)

Hemogram values; median (IQR)

 

Leukocyte count

7800 (6500–9400)

Neutrophil, %

62.9 (54.3–71.1)

Eosinophil, %

2.2 (1.0–4.0)

Pulmonary function tests; median (IQR)

 

Post bronchodilator FEV1/FVC, %

56 (40.2–72.2)

Post bronchodilator FEV1, %

56 (47–63.4)

COPD subtypes, n (%)

 

GOLD I

29 (13.6)

GOLD II

107 (50.2)

GOLD III

52 (24.4)

GOLD IV

25 (11.8)

Group A

112 (52.6)

Group B

39 (18.3)

Group C

21 (9.9)

Group D

41 (19.2)

Treatment, n (%)

 

LABA + LAMA + ICS

66 (30.99)

LABA + LAMA

76 (35.68)

LABA + ICS

18 (8.45)

LAMA + ICS

1 (0.47)

LAMA only

36 (16.9)

LABA only

12 (5.63)

No inhaler treatment

4 (1.88)

ACO, n (%)

19 (8.92)

Exacerbations per year; median (IQR)

1 (0–1)

  1. BMI, body mass index; FEV1/FVC, first second of forced expiration/ forced vital capacity; LAMA, long acting muscarinic antagonist; LABA, long-acting β2-agonists; ICS, inhaled corticosteroids; ACO, asthma-COPD overlap; interquartile range (IQR, Q1–Q3)